Indacaterol Maleate Patent Expiration

Indacaterol Maleate is Used for managing airflow obstruction in patients with COPD. It was first introduced by Novartis Pharmaceuticals Corp in its drug Arcapta Neohaler on Jul 1, 2011.


Indacaterol Maleate Patents

Given below is the list of patents protecting Indacaterol Maleate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Arcapta Neohaler US8479730 Inhaler device Oct 11, 2028 Novartis
Arcapta Neohaler US6878721 Beta2-adrenoceptor agonists Feb 25, 2025 Novartis
Arcapta Neohaler US8067437 Beta-2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Arcapta Neohaler US8658673 BETA2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Arcapta Neohaler US8796307 Beta2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis



Indacaterol Maleate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List